In obese patients without malignancy, a very-low-calorie KD reduces visceral adiposity and obesity-related metabolic dysfunction, restores leptin and resistin levels to normal, and reduces the expression of inflammatory markers.227–229 This approach might therefore be particularly valuable for cancer populations where weight loss is a critical priority. The gene discussed is LEP; the disease is Obesity.